Roles of TNF-α gene polymorphisms in the occurrence and progress of SARS-CoV infection: A case-control study

Shixin Wang†1, Maoti Wei*†2, Yi Han1, Keju Zhang1, Li He1, Zhen Yang1, Bing Su3, Zhilun Zhang4, Yilan Hu2 and Wuli Hui2

Address: 1Proteomics Laboratory, Medical College of Chinese People’s Armed Police Force, Tianjin, China, 2Department of Epidemiology, Medical College of Chinese People’s Armed Police Force, Tianjin, China, 3Department of Respiratory, Pingjin Hospital, Medical College of Chinese People’s Armed Police Force, Tianjin, China and 4Department for Emergency Diseases, Center for Disease Control and Prevention, Tianjin, China

Email: Shixin Wang - Wshx-001@163.com; Maoti Wei* - weimaoti@yahoo.com.cn; Yi Han - halanhan2001sh@163.com; Keju Zhang - sinong77@sina.com; Li He - wujinhl@163.com; Zhen Yang - yzdtchina@yahoo.com.cn; Bing Su - tjsubit553@sina.com; Zhilun Zhang - zz718@sina.com.cn; Yilan Hu - yougu@yahoo.com.cn; Wuli Hui - huiwuli@163.com
* Corresponding author †Equal contributors

Abstract

Background: Host genetic factors may play a role in the occurrence and progress of SARS-CoV infection. This study was to investigate the relationship between tumor necrosis factor (TNF)-α gene polymorphisms with the occurrence of SARS-CoV infection and its role in prognosis of patients with lung interstitial fibrosis and femoral head osteonecrosis.

Methods: The association between genetic polymorphisms of TNF-α gene and susceptibility to severe acute respiratory syndromes (SARS) was conducted in a hospital-based case-control study including 75 SARS patients, 41 health care workers and 92 healthy controls. Relationships of TNF-α gene polymorphisms with interstitial lung fibrosis and femoral head osteonecrosis were carried out in two case-case studies in discharged SARS patients. PCR sequencing based typing (PCR-SBT) method was used to determine the polymorphisms of TNF-α gene in locus of the promoter region and univariate logistic analysis was conducted in analyzing the collected data.

Results: Compared to TT genotype, the CT genotype at the -204 locus was found associated with a protective effect on SARS with OR(95%CI) of 0.95(0.90–0.99). Also, TT genotype, CT and CC were found associated with a risk effect on femoral head necrosis with ORs(95%CI) of 5.33(1.39–20.45) and 5.67(2.74–11.71), respectively and the glucocorticoid adjusted OR of CT was 5.25(95%CI 1.18–23.46) and the combined (CT and CC) genotype OR was 6.0 (95%CI 1.60–22.55) at -1031 site of TNF-α gene. At the same time, the -863 AC genotype was manifested as another risk effect associated with femoral head necrosis with OR(95%CI) of 6.42(1.53–26.88) and the adjusted OR was 8.40(95%CI 1.76–40.02) in cured SARS patients compared to CC genotype.

Conclusion: SNPs of TNF-α gene of promoter region may not associate with SARS-CoV infection. And these SNPs may not affect interstitial lung fibrosis in cured SARS patients. However, the -1031CT/CC and -863 AC genotypes may be risk factors of femoral head necrosis in discharged SARS patients.
Background

TNF, the gene encoding tumour necrosis factor (TNF), resides in the central part (class III region) of the major histocompatibility complex (MHC) surrounded by a large number of other immunological genes [1]. Because of the special locus of this gene, it can be deduced that this gene may associate with many diseases, and this hypothesis was confirmed by many research results [2,3]. TNF-α is a key mediator of the inflammatory response and is critical for host defense against a wide variety of pathogenic microbes. However, the over-expression of this cytokine may lead to badness in disease recovery. The dual role of TNF, acting as an agent of both innate immunity and inflammatory pathology, poses a considerable challenge for gene regulation [2], and this regulation mainly located on promoter region of this gene. The capacity for cytokine production in an individual has a major genetic component, and striking differences existed among individuals in terms of their ability to produce cytokines. Several biallelic polymorphisms had been described within the TNF-α gene, including seven in the promoter region at positions -1031T→C, -863C→A, -857C→T, -376G→A, -308G→A, -238G→A and -163G→A base pairs from the transcription start site [4,5]. Moreover, a number of studies had shown that the TNF-α promoter polymorphism had a significant effect on its transcriptional activity [6,7].

Severe acute respiratory syndrome (SARS) is a newly described human infectious disease caused by a novel coronavirus-SARS-CoV. SARS-CoV infection is important because of its high infectivity and unpredictable clinical course, which is characterized by a high mortality rate [8]. Till now, many researchers had reported that susceptibilities to infection SARS-CoV may associated with HLA, MXA, OAS-1 and CLEC4M gene polymorphisms [9-13], yet these results were variable in different populations. For example, Ng reported that SARS-CoV infection was associated with HLA-B*0703 and HLA-DRB1*0301 in HongKong population [9], however, Lin's results showed that HLA-B*4601 and HLA-B*5401 were closely related to SARS-CoV infection [10]. Chan reported that CLEC4M was attributed to SARS-CoV infection [13], but Zhi's results failed to support this conclusion.7 These differences may be attributed to the study population used in each report, also the complex mechanism infection to SARS-CoV should be considered as another factor of these differences. In order to explore more host factors influencing the occurrence of SARS-CoV infection, we studied the polymorphisms of TNF-α gene at the promoter region, which had been ascribed to polymorphisms within the regulatory regions or signal sequences of cytokine genes [14].

After discharging from hospital, interstitial lung fibrosis was observed in SARS patients. Clinical data showed that the prevalence rate of this change was 21%(42/200) in cured SARS patients nine months from the discharge [15]. TNF-α was one of the earliest cytokines implicated in the pathogenesis of lung fibrosis diseases and, together with IL-1, has been found to over-expressed in regenerated type II pneumocytes in human lung, thus enhanced fibroblast proliferation [16]. TNF-α polymorphisms have been discovered significantly associated with increased risk of developing pulmonary fibrosis [17,18]. Given that genetic variation may potentially alter inflammation and fibrosis in the lung, the aim of this case-control study was to examine the TNF-α polymorphisms with interstitial lung fibrosis in SARS patients.

In spite of interstitial lung fibrosis in cured SARS patients, another sequela – femoral head necrosis was also observed in this population and the prevalence rate was 22.07%(49/221) and 23.1%(18/78) in Tianjin and Beijing patients respectively [15,19]. The cause of this disease was still unknown and there were arguments about it. For example, some author considered SARS-CoV as the cause of femoral head necrosis, yet other authors disagreed with this view [20,21]. Previous studies showed that femoral head necrosis may caused by hormone usage [20], yet our data failed to agree with this point. So, it need further study to explore the cause of this sequela and TNF-α polymorphisms were considered first in this report.

In this paper, we aimed to study whether polymorphisms in TNF-α promoter region were associated with SARS-CoV infection, development, and progression of interstitial lung fibrosis and femoral head necrosis in cure SARS patients.

Methods

Subjects

This study was reviewed and approved by ethics committees in the Medical College of CPAFP. The study population comprised 75 SARS patients in Pingjin hospital, Tianjin, China, 41 health care workers of the same hospital, who had come into contact with SARS patients but had not developed into SARS, and 66 individuals having no contact history with SARS patients. Among 75 SARS patients, 55 could be classified into severe and light SARS according to their clinical condition history during the hospitalized period and this population also had the history of hormone therapy by reviewing the clinical treatment. Anti-SARS-CoV antibodies of the serum samples were tested by SARS ELISA kits (Huada Diagnostics Ltd, Beijing, China).

Considered that the progression of interstitial lung fibrosis or femoral head necrosis may be affected by hormone therapy, hormone using dosage, method and lasting period were considered in this study when analyzing the
associations between gene polymorphisms with disease. Three kinds of hormone were used in SARS patients including methylprednisolone, deltadehydrocortisone and dexamethasone. In order to simplify analyzing, deltadehydrocortisone and dexamethasone dosage were calculated into methylprednisolone using the following equation: 4 mg methylprednisolone = 5 mg deltadehydrocortisone = 0.75 mg dexamethasone. Lash therapy means more than 320 mg methylprednisolone were used in a single day.

Cured SARS patients with interstitial lung fibrosis were diagnosed by respiratory experts according to CT results following the standard proposal for therapy and diagnosis of SARS patients issued by Chinese Ministry of Health in 2004 [22]. Interstitial lung fibrosis of SARS patients manifested as irregular patch and strip shadow or high density strip shadow and honeycomb interstitial lung fibrosis, these changes could combine with the bronchiectasis.

Femoral head necrosis was diagnosed using magnetic resonance imaging (MRI). An MRI scan of a normal femoral head would show uniformly high signal intensity on T1- and T2-weighting throughout the femoral head. Agree with one of the following image could be diagnosed as femoral head necrosis in SARS patients: Abnormal signal with clear margin in cartilage of femoral head, or double thread image, or fracture or joint dent under cartilage, or T1WI low signal, T2WI and STIR high signal of the marrow cavity edema with blur edge [22].

Genomic DNA extraction and polymerase chain reaction
Leucocytes were isolated within 12 h of blood collection using Percoll reagent. Then genomic DNA was extracted using cell DNA extraction kit (Tiangen BioTec Co, Beijing, China). Amplification was carried out in molecular BioProducts 200 μL capped tubes, as these gave optimal heat transfer in the thermal cycler.

Sequencing of TNF-α gene fragments
The TNF-α gene 1279 bp fragments in this paper were sequenced in double directions with forward primer 5’-GATGGACTCACCAGGTGAG-3’ and reverse primer 5’-CTCATGGTGTTCCCCAGG-3’ and Invitrogen company (Invitrogen Co, Shanghai, China) using ABI 373 thermal cycler carried out this job. The homozygote genotype of each SNP site manifested as a single peak, yet the heterozygote with an ambiguous nucleotide position of a double color peak in the Big Dye chemistry pictures. According to reading the sequence graphs, the genotype was determined.

Statistics
The differences in values between two groups were evaluated by Chi analysis for frequencies or student t test for quantitative index and binary logistic regression was done using SPSS 11.5 software (SPSS Inc, Chicago, Illinois, USA).

Results
Demographic characteristics of the populations
A total of 75 SARS patients, 41 health care workers and 66 individuals were included in this study. All the populations were Chinese Han ethnic. The mean age was 35.0 years for SARS, 35.7 for health care workers and 30.1 for individual controls (SARS Vs HCW, P < 0.05; SARS Vs individual control, P > 0.05). The proportion of male was 30.6% in SARS, 26.8% in health care workers and 69.5% in individual controls (SARS Vs HCW, P > 0.05; SARS Vs individual control, P < 0.05). The sera positive rate anti-SARS-CoV antibody was 100.0% in SARS, significantly higher than that of health care workers and individual controls (SARS Vs HCW, P < 0.05; SARS Vs individual control, P < 0.05) (Table 1).

TNF-α polymorphisms and SARS-Cov infection
TNF-α genotype frequencies were variable in SARS, health care workers and individual controls. There were no differences of TNF-α genotype distribution at the -1031(T→C), -863(C→A), -572(A→C), -308(G→A) and -

Table 1: Demographic characteristics of the populations

| Characteristics               | SARS (N = 75) | Health care workers (N = 41) | Control (N = 92) |
|------------------------------|---------------|------------------------------|------------------|
| Age(years), mean [range]     | 35.0 [16-78]  | 35.7 [25-55]                 | 30.1 [17-56]     |
| Gender (Male/Female)         | 23/52         | 11/30                        | 68/24            |
| Positive rate of anti-SARS-CoV Ab | 100.0%(75/75) | 2.4%(1/41)                   | 0.0%(0/92)       |
238(G→A) among the three populations. However, the CT genotype was less frequent in SARS group when compared with individual controls at the -204 locus ($X^2 = 4.20, P = 0.04$). Compared to TT genotype, the CT genotype at the -204 locus were found associated with a protective effect on SARS with OR(95%CI) of 0.95(0.90–0.99) (Table 2).

According to the clinical history, symptoms of SARS patients were classified into light and severe. Because of the complicated clinical condition during SARS outbreak, some patients’ histories were incomplete and could not be classified following the severity standard [22]. The severe SARS referred to those with one or more of the following: (1) dyspnea, more than 30 times per min respiratory frequencies in still condition,(2) oxygenation index less than 300 mmHg; (3) shock or multiple organ dysfunction syndrome. Among all 75 patients, fifty-four were classified into light and severe. And there were no association of TNF-α polymorphisms and SARS severity (Table 3).

Glucocorticoid using in SARS with interstitial lung fibrosis or femoral head necrosis

Glucocorticoid using dosage, method and lasting period were not associated with interstitial lung fibrosis or femoral head necrosis in binary logistic analysis in SARS patients (Table 4). And there was no difference of hormone using dosage between the interstitial lung fibrosis and non-interstitial lung fibrosis group($t = 0.72, P = 0.47$) and this trend was also observed in the femoral head necrosis and non-femoral head necrosis group($t = 1.90, P = 0.064$) (Table 5).

TNF-α polymorphisms and interstitial lung fibrosis

Allele frequencies of TNF-α polymorphisms were listed in Table 6 and there were no significant differences between interstitial lung fibrosis and non-interstitial lung fibrosis in SARS patients at promoter region of TNF-α gene.

TNF-α polymorphism and femoral head necrosis

Allele frequencies of TNF-α gene were compared in SARS patients between femoral head necrosis and non-femoral head necrosis (Table 7). The -1031 CT and CC genotypes were more frequent in SARS patients with femoral head necrosis(53.7% and 6.7%, respectively) than in non-femoral head necrosis(20.0% and 0.0%, respectively). Compared to TT genotype, CT and CC were found associated with a risk effect on femoral head necrosis with ORs(95%CI) of 5.33(1.39–20.45) and 5.67(2.74–11.71), respectively. The adjusted OR of CT was 5.25(95%CI 1.18–23.46) and the combined (CT and CC) genotype OR was 6.0 (95%CI 1.60–22.55). Also, the -863 AC genotype accounted for 43.7% of femoral head necrosis group but 10.8% of non-femoral head necrosis. Compared to CC genotype, the AC genotype was manifested as another risk effect associated with femoral head necrosis with OR(95%CI) of 6.42(1.53–26.88) and the adjusted OR was 8.40(95%CI 1.76–40.02) in cured SARS patients.

Discussion

Four years after SARS occurrence, many problems still remained unknown to us. Till now, many researchers have reported that susceptibility to infection SARS-CoV may associate with HLA, MXA, OAS-1 and CLEC4M gene polymorphisms, yet the results are variable in different populations [9-13]. These differences may be attributed to the study population used in each report, also the complex mechanism infection to SARS-CoV should be considered as another factor of these differences. In order to explore more host factor influence the occurrence of SARS-CoV infection, we studied the polymorphisms of TNF-α gene at the promoter region, which have been ascribed to polymorphisms within the regulatory regions or signal sequences of cytokine genes [14]. Allele distributions at -1031, -863, -857, -572, -238 and -163 were almost the same among the SARS, the health care workers and individual controls, but a higher A allele frequency in SARS population when compared with the control at the -308 locus($X^2 = 8.96, P = 0.003$). Though previous study showed that TNF-α -308 AG genotype was associated with the clearance of Hepatitis B virus and the infection of Helicobacter pylori cagA subtype infection [24,25], our results failed to show the role of this locus in SARS-CoV infection and this conclusion agreed with that of Chong WP et al [26]. We found that there was a weak protective effect of CT genotype at -204 locus of TNF-α gene against SARS-CoV infection. The -204 locus was a new discovered SNP site of TNF-α promoter region and its role in infectious diseases might need further study. At the same time, no obvious association between the polymorphisms of TNF-α promoter region with the severity of SARS was observed. However, Lu reported that the -238G/A polymorphism of TNF-α associated with the outcomes of hepatitis B virus infection [27]. Thus, the roles of TNF-α gene in infectious diseases should be further studied.

TNF-α, a key mediator of the inflammatory response, is critical for host defense against a wide variety of pathogenic microbes, but a higher concentration of this cytokine may cause severe pathology. The capacity for cytokine production in an individual has a major genetic component, and striking differences existed among individuals in terms of their ability to produce cytokines. A number of studies had shown that the TNF-α promoter polymorphism has a significant effect on transcriptional activity [6,7]. During the process of SARS-CoV infection, there was a cytokine storm in patients including IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-γ, TNF-α and TGF-β[128]. The elevated levels of pro-inflammatory cytokines which may cause immuno-mediated damage to lung and other
Table 2: TNF-α gene polymorphism in promoter region in cured SARS patients, health care workers and individual control

| SNP site | SARS (%) | Health Care Workers (%) | Individual Control (%) | OR¹ (95%CI) | OR² (95%CI) |
|----------|----------|-------------------------|------------------------|-------------|-------------|
| -1031    |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| TT       | 45(63.4) | 25(64.1)                | 61(67.8)               | -           | -           |
| CT       | 23(32.4) | 13(33.3)                | 27(30.0)               | 0.98(0.43–2.27) | 1.12(0.59–2.27) |
| CC       | 3(4.2)   | 1(2.6)                  | 2(2.2)                 | 1.67(0.17–16.88) | 2.03(0.33–12.68) |
| Allele   |          |                         |                        |             |             |
| T        | 79.6     | 80.8                    | 74.5                   |             |             |
| C        | 20.4     | 19.2                    | 25.5                   |             |             |
| -863     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| CC       | 55(73.3) | 29(72.5)                | 64(70.3)               | -           | -           |
| AC       | 19(25.3) | 1(27.5)                 | 27(29.7)               | 0.91(0.38–2.17) | 0.82(0.41–1.63) |
| AA       | 1(1.3)   | 0                       | 0                      | 0.98(0.94–1.07) | 2.16(1.78–2.63) |
| Allele   |          |                         |                        |             |             |
| C        | 86.0     | 86.3                    | 85.2                   |             |             |
| A        | 14.0     | 13.7                    | 14.8                   |             |             |
| -857     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| CC       | 56(74.7) | 31(77.5)                | 66(72.5)               | -           | -           |
| CT       | 19(25.3) | 8(20.0)                 | 20(27.5)               | 1.32(0.52–3.35) | 0.89(0.45–1.79) |
| TT       | 0        | 1(2.5)                  | 0                      | 1.03(0.97–1.1) | -           |
| Allele   |          |                         |                        |             |             |
| C        | 86.0     | 86.3                    | 85.2                   |             |             |
| T        | 14.0     | 13.7                    | 14.8                   |             |             |
| -572     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| AA       | 73(97.3) | 40(97.6)                | 90(97.8)               | -           | -           |
| AC       | 2(2.7)   | 4(2.4)                  | 2(2.2)                 | 1.10(0.10–12.46) | 1.23(0.17–8.97) |
| Allele   |          |                         |                        |             |             |
| A        | 98.7     | 98.8                    | 98.9                   |             |             |
| C        | 1.3      | 1.2                     | 1.1                    |             |             |
| -308     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| GG       | 67(89.3) | 39(95.1)                | 88(95.7)               | -           | -           |
| AG       | 7(9.1)   | 2(4.9)                  | 4(4.3)                 | 2.04(0.40–10.30) | 2.30(0.65–8.18) |
| AA       | 1(1.3)   | 0                       | 0                      | 0.98(0.96–1.01) | 2.31(1.93–2.77) |
| Allele   |          |                         |                        |             |             |
| G        | 94.0     | 97.6                    | 100.0                  |             |             |
| A        | 6.0      | 2.4                     | 0.0                    |             |             |
| -238     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| GG       | 65(86.7) | 39(95.1)                | 84(91.3)               | -           | -           |
| AG       | 10(13.3) | 4(4.9)                  | 10(4.3)                | 2.04(0.40–10.30) | 2.30(0.65–8.18) |
| Allele   |          |                         |                        |             |             |
| G        | 93.3     | 97.6                    | 95.7                   |             |             |
| A        | 6.7      | 2.4                     | 4.3                    |             |             |
| -204     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| TT       | 75(100)  | 41(100.0)               | 87(94.6)               | -           | -           |
| CT       | 0(0.0)   | 0                       | 5(5.4)                 | -           | 0.95(0.90–0.99) |
| Allele   |          |                         |                        |             |             |
| T        | 100.0    | 100.0                   | 97.3                   |             |             |
| C        | 0.0      | 0.0                     | 2.7                    |             |             |
| -163     |          |                         |                        |             |             |
| Genotype |          |                         |                        |             |             |
| GG       | 74(98.7) | 41(100.0)               | 87(94.6)               | -           | -           |
| CG       | 1(1.3)   | 0                       | 5(5.4)                 | 0.98(0.96–1.01) | 0.24(0.03–2.06) |
| Allele   |          |                         |                        |             |             |
| G        | 99.3     | 100.0                   | 97.3                   |             |             |
| C        | 0.7      | 0.0                     | 2.7                    |             |             |

Note: OR¹ was calculated by comparing SARS with HCW; OR² was calculated by comparing SARS with individual control; &: Odds ratio replaced with SARS group; $: Odds ratio replaced with control
### Table 3: TNF-α gene polymorphism and the progress of SARS

| SNP site | Severe SARS(%) | Light SARS(%) | OR* (95% CI) | P   |
|----------|----------------|---------------|--------------|-----|
| -1031    |                |               |              |     |
| Genotype |                |               |              |     |
| TT       | 13(61.9)       | 22(73.3)      | 1.48(0.44–5.04) | 0.53 |
| CT       | 7(33.3)        | 8(26.7)       |               |     |
| CC       | 1(4.8)         | 0(0.0)        | 2.69(1.75–4.14) | 0.39 |
| Allele   |                |               |              |     |
| T        | 78.6           | 86.7          |              |     |
| C        | 21.4           | 13.3          |              |     |
| -863     |                |               |              |     |
| Genotype |                |               |              |     |
| CC       | 19(79.2)       | 24(80.0)      | 1.05(0.28–3.98) | 0.60 |
| AC       | 5(20.8)        | 6(20.0)       |              |     |
| Allele   |                |               |              |     |
| C        | 89.6           | 90.0          |              |     |
| A        | 10.4           | 10.0          |              |     |
| -857     |                |               |              |     |
| Genotype |                |               |              |     |
| CC       | 15(62.5)       | 24(80.0)      | 2.40(0.71–8.11) | 0.15 |
| CT       | 9(37.5)        | 6(20.0)       |              |     |
| Allele   |                |               |              |     |
| C        | 39(81.2)       | 54(90.0)      |              |     |
| T        | 9(18.8)        | 6(10.0)       |              |     |
| -572     |                |               |              |     |
| Genotype |                |               |              |     |
| AA       | 24(100.0)      | 29(96.7)      | 1.83(1.43–2.34) | 1.00 |
| AC       | 0(0.0)         | 1(3.3)        |              |     |
| Allele   |                |               |              |     |
| A        | 100.0          | 98.3          |              |     |
| C        | 0.0            | 1.7           |              |     |
| -308     |                |               |              |     |
| Genotype |                |               |              |     |
| GG       | 20(83.3)       | 27(90.0)      | 2.70(0.45–16.22) | 0.39 |
| AG       | 4(16.7)        | 2(6.7)        |              |     |
| AA       | 0(0.0)         | 1(3.3)        | 1.74(1.36–2.23) | 1.00 |
| Allele   |                |               |              |     |
| G        | 100.0          | 93.3          |              |     |
| A        | 0.0            | 6.7           |              |     |
| -238     |                |               |              |     |
| Genotype |                |               |              |     |
| GG       | 20(83.3)       | 27(90.0)      | 1.80(0.36–8.96) | 0.69 |
| AG       | 4(16.7)        | 3(10.0)       |              |     |
| AA       | 0(0.0)         | 1(3.3)        |              |     |
| Allele   |                |               |              |     |
| G        | 91.70          | 95.0          |              |     |
| A        | 8.3            | 5.0           |              |     |
| -204     |                |               |              |     |
| Genotype |                |               |              |     |
| TT       | 24(100.0)      | 30(100.0)     |              |     |
| Allele   |                |               |              |     |
| T        | 100.0          | 100.0         |              |     |
| -163     |                |               |              |     |
| Genotype |                |               |              |     |
| GG       | 24(100.0)      | 30(100.0)     |              |     |
| Allele   |                |               |              |     |
| G        | 100.0          | 100.0         |              |     |

**Note:** OR was calculated using light SARS as control.

*: Odds ratio replaced with severity SARS group;

&: Odds ratio replaced with light SARS

$: Odds ratio replaced with light SARS
organs, resulting in acute lung injury and, subsequently, multi-organ dysfunction [29]. So, TNF-α genetic variation may potentially alter inflammation and fibrosis in the lung. After discharging from hospital, interstitial lung fibrosis was observed in cured SARS patients and the prevalence rate was 21%(42/200). TNF-α was one of the earliest cytokines implicated in the pathogenesis of lung fibrosis disease and, together with IL-1, has been found to over-express in regenerating type II pneumocytes in human lung, thus enhancing fibroblast proliferation [16]. TNF-α genetic polymorphisms have been found significantly associated with increased risk of developing pulmonary fibrosis [17,18]. During the progress of idiopathic pulmonary fibrosis, activated epithelial cells are thought to release potent fibrogenic molecules and cytokines, such as TNF-α and TGF-β1, which in turn foster the transformation of fibroblasts into myofibroblasts and promote their production of extracellular matrix molecules and a vicious cycle of injury and abnormal epithelial healing sets the stage for progressive fibrosis and architectural distortion of the lung parenchyma [7]. However, our data failed to show that alleles at -1031(T→C), -863(C→A), -857(C→T), -572(A→C), -308(G→A) and -238(G→A) were related to interstitial lung fibrosis when compared with non-interstitial lung fibrosis in SARS patients. At the same time, -204 and -163 were homozygote genotype of TT and GG respectively in SARS patients and no relationship of genotype with interstitial lung fibrosis could be calculated. This result implicated that there maybe a different mechanism of interstitial lung fibrosis of SARS compared with idiopathic pulmonary fibrosis.

Femoral head necrosis, another sequela of discharged SARS patients, prevailed with a rate of 22.07%(49/221) in Tianjin [15]. However, the cause of this sequela was still unknown and there were arguments about it. For example, some author considered SARS-CoV as the cause of femoral head necrosis, yet other authors disagree with this view [20,21]. Previous studies showed that femoral head necrosis may caused by hormone usage, our data was far to agree with this conclusion. There was no obvious association between hormone using including hormone dosage, method and lasting period with femoral head necrosis in binary logistic analysis in SARS patients. We found that the -1031 CT and CC genotypes were more frequent in SARS patients with femoral head necrosis(53.7% and 6.7%, respectively) than in non-femoral head necrosis(20.0% and 0.0%, respectively). And CT and CC were related with a risk effect on femoral head necrosis with ORs (95%CI) of 5.33(1.39–20.45) and 5.67(2.74–11.71), respectively when compared to TT genotype. The hormone using adjusted OR of CT was 5.25(95%CI 1.18–23.46) and the combined (CT and CC) genotype OR was 6.0 (95%CI 1.60–22.55). Also, the -863 AC genotype accounted for 43.7% of femoral head necrosis group but 10.8% of non-femoral head necrosis. Compared to CC genotype, the AC genotype was manifested as another risk effect associated with femoral head necrosis with OR(95%CI) of 6.42(1.53–26.88) and the adjusted OR was 8.40(95%CI 1.76–40.02) in cured SARS patients.

Table 4: Binary logistic analysis of hormone using in SARS patients

| Factors     | Interstitial lung fibrosis | Femoral head necrosis |
|-------------|---------------------------|-----------------------|
|             | P  | OR  | 95.0% C.I. | P  | OR  | 95.0% C.I. |
| Glucocorticoid | 0.97 | 1.00 | 0.99 | 1.00 | 0.11 | 1.00 | 0.99 |
| Time        | 0.78 | 0.97 | 0.81 | 1.18 | 0.96 | 1.00 | 0.84 |
| Lash therapy | 0.51 | 2.13 | 0.23 | 20.13 | 0.27 | 0.32 | 0.04 |
| Constant    | 0.68 | 3.48 | 0.13 | 88.28 |   |   |   |

Table 5: Cumulative hormone usage (mg) in cured SARS patients classified according to interstitial lung fibrosis or femoral head necrosis

|                  | Mean ± SD | Median | P25 | P75 |
|------------------|-----------|--------|-----|-----|
| Interstitial lung fibrosis |           |        |     |     |
| Yes              | 5188.13 ± 2037.56 | 5140.00 | 3110.00 | 7288.75 |
| No               | 4493.11 ± 2528.91 | 3895.00 | 2720.00 | 5975.00 |
| Femoral head necrosis |           |        |     |     |
| Yes              | 5672.31 ± 2328.61 | 6090.00 | 3437.50 | 7872.50 |
| No               | 4187.81 ± 2389.71 | 3807.50 | 2355.00 | 5707.50 |

*: hormone dosage between interstitial lung fibrosis and non-interstitial lung fibrosis, t = 0.72, P = 0.47.

**: hormone dosage between femoral head necrosis and non-femoral head necrosis, t = 1.90, P = 0.064
TNF-α can activate activity of osteoclasts and accelerate absorption of the bone and cartilage and induce occurrence of oxygen free radicals and lipid peroxidation, which can induce ischemic necrosis of the femoral head [30]. So, the polymorphism TNF-α gene may be directly or indirectly attributed to the occurrence of femoral head necrosis in SARS patients.

**Table 6: TNF-α gene polymorphisms and the occurrence of interstitial lung fibrosis in SARS patients**

| SNP site | Interstitial lung fibrosis(%) | Non-interstitial lung fibrosis(%) | OR* (95%C.I.) | P      |
|----------|------------------------------|----------------------------------|---------------|--------|
| -1031    | Genotype                     |
|          | TT                          | 14(70)                           | 12(57.1)      | 0.64(0.17–2.38) | 0.51 |
|          | CT                          | 6(30)                            | 8(38.1)       | 0.08(0.93–1.27) | 0.48 |
|          | CC                          | 0                                | 1(4.8)        |
| Allele   | T                           | 85.00                            | 76.19         |
|          | C                           | 15.00                            | 23.81         |
| -863     | Genotype                     |
|          | CC                          | 17(77.3)                         | 16(72.7)      | 0.78(0.20–3.08) | 0.73 |
|          | AC                          | 5(22.7)                          | 6(27.3)       |
| Allele   | C                           | 88.64                            | 38            |
|          | A                           | 11.36                            | 13.64         |
| -857     | Genotype                     |
|          | CC                          | 15(68.8)                         | 17(77.3)      | 1.59(0.42–6.07) | 0.50 |
|          | CT                          | 7(31.8)                          | 5(22.7)       |
| Allele   | C                           | 84.09                            | 88.64         |
|          | T                           | 15.91                            | 11.36         |
| -572     | Genotype                     |
|          | AA                          | 21(95.5)                         | 22(100)       |
|          | AC                          | 1(4.5)                           | 0             | 0.96(0.87–1.05)‡ | 0.50 |
| Allele   | A                           | 97.73                            | 100.00        |
|          | C                           | 2.27                             | 0.00          |
| -308     | Genotype                     |
|          | GG                          | 21(95.5)                         | 18(81.8)      |
|          | AG                          | 1(4.5)                           | 4(18.2)       | 0.21(0.02–2.10) | 0.17 |
| Allele   | G                           | 97.73                            | 90.9          |
|          | A                           | 2.27                             | 9.1           |
| -238     | Genotype                     |
|          | GG                          | 20(90.9)                         | 18(81.8)      |
|          | AG                          | 2(9.1)                           | 4(18.2)       | 0.45(0.07–2.76) | 0.33 |
| Allele   | G                           | 95.45                            | 90.9          |
|          | A                           | 4.55                             | 9.1           |

**Note:***: OR was calculated using non-interstitial lung fibrosis as control.  
‡: Odds ratio replaced with interstitial lung fibrosis group;  
‡: Odds ratio replaced with non-interstitial lung fibrosis group

**Conclusion**

In conclusion, there may be no association of TNF-α polymorphisms in promoter region with SARS-Cov infection. Also, TNF-α gene polymorphisms may no affect the occurrence of interstitial lung fibrosis in cured SARS patients. However, the polymorphisms may relate with femoral head necrosis.
Table 7: TNF-α gene polymorphism and femoral head necrosis in cured SARS patients.

| SNP site | Femoral head necrosis (%) | Non-femoral head necrosis (%) | OR* (95%C.I.) | P  |
|----------|---------------------------|-------------------------------|---------------|----|
| -1031    |                           |                               |               |    |
| Genotype |                           |                               |               |    |
| TT       | 6(40)                     | 28(80)                        | 5.33(1.39–20.45) | 0.01 |
| CT       | 8(53.7)                   | 7(20)                         | 5.67(2.74–11.71) | 0.04 |
| CC       | 1(6.7)                    | 0                             |               |    |
| Allele   |                           |                               |               |    |
| T        | 66.67                     | 90.00                         |               |    |
| C        | 33.33                     | 10.00                         |               |    |
| -863     |                           |                               |               |    |
| Genotype |                           |                               |               |    |
| CC       | 9(56.3)                   | 33(89.2)                      | 6.42(1.53–26.88) | 0.01 |
| AC       | 7(43.7)                   | 4(10.8)                       |               |    |
| Allele   |                           |                               |               |    |
| C        | 78.12                     | 94.59                         |               |    |
| A        | 21.88                     | 5.41                          |               |    |
| -857     |                           |                               |               |    |
| Genotype |                           |                               |               |    |
| CC       | 12(75)                    | 26(70.3)                      | 0.78(0.21–2.99) | 0.73 |
| CT       | 4(25)                     | 11(29.7)                      |               |    |
| Allele   |                           |                               |               |    |
| C        | 87.50                     | 85.14                         |               |    |
| T        | 12.50                     | 14.86                         |               |    |
| -572     |                           |                               |               |    |
| Genotype |                           |                               |               |    |
| AA       | 16(100)                   | 36(97.3)                      | 1.44(1.21–1.73) | 0.70 |
| AC       | 0                         | 1(2.7)                        |               |    |
| Allele   |                           |                               |               |    |
| A        | 100                       | 98.7                          |               |    |
| C        | 0                         | 1.3                           |               |    |
| -308     |                           |                               |               |    |
| Genotype |                           |                               |               |    |
| GG       | 14(87.5)                  | 32(86.5)                      | 1.14(0.19–6.98) | 0.89 |
| AG       | 2(12.5)                   | 4(10.8)                       |               |    |
| AA       | 0                         | 1(2.7)                        | 1.44(1.19–1.74) | 0.70 |
| Allele   |                           |                               |               |    |
| G        | 93.7                      | 91.89                         |               |    |
| A        | 6.25                      | 8.11                          |               |    |
| -238     |                           |                               |               |    |
| Genotype |                           |                               |               |    |
| GG       | 13(81.3)                  | 33(89.2)                      | 1.90(0.37–9.71) | 0.35 |
| AG       | 3(18.7)                   | 4(10.8)                       |               |    |
| Allele   |                           |                               |               |    |
| G        | 90.62                     | 94.59                         |               |    |
| A        | 9.38                      | 5.41                          |               |    |

Note: *: OR was calculated using non-femoral head necrosis as control.
$: OR replaced by femoral head necrosis;
‡: OR estimated by non-femoral head necrosis;

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
SXW conceived of the study, and participated in its design and coordination.

MTW, co-first author, carried out the molecular genetic studies and drafted the manuscript.

YH, KJZ and LH carried out the molecular genetic studies

ZY, BS and ZLZ participated in field investigation and samples collection of the study.
YLH and WLH participated in the design of the study and performed the statistical analysis

All authors contributed to writing of the final manuscript

All authors read and approved the final manuscript

Acknowledgements

This paper was supported by the Tianjin Science Fund (No. 05YFSZSF02900) and the Science Fund of Medical College of CPAPF (No. WYV-2005-14).

References

1. The MHC sequencing consortium: Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature 1999, 401:921-923.
2. Sariban E, Imamura K, Luebeers R, Kufe D: Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest 1988, 81:5106-10.
3. Field TJ, Fojo AT, Ackerman H, Uyen J, Kazandjian P, Taylor T, Molyneux M, Pinder M, Kwaistowski D: Nucleotide diversity of the TNF gene region in an African village. Genes and Immunity 2001, 2:343-348.
4. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itok K: Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998, 51:605-612.
5. Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, Kowalski M, Lech PIE, Barsegio L, Coiffier B, et al.: Human leucocyte antigen class II and tumor necrosis factor gene genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002, 100:3037-3040.
6. Kroeger KM, Carville KS, Abraham LJ: The -308 tumour necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
7. Verma S, Slutsky AS: Idiopathic Pulmonary Fibrosis-New Insights. N Engl J Med 2007, 356(13):1370-1371.
8. Lee N, Hui D, Xiao Y, Tian Q, Chen L, Zhao H, Chen W: Dynamic changes of serum SARS-Coronavirus IgG, pulmonary function and radiography in patients recovering from SARS after hospital discharge. Respiratory Research 2005, 6:15-11.
9. Gu JY, Wang SX, Cao X, Hui WL, Li YM, Yang Z, SL Bu: Baseline case-control study of avascular necrosis of femoral head during SARS patients’ convalescence. Acta Academiae Medicinae CPAPF 2005, 14(1):1-13.
10. Li Y, Wang SX, Gao HS, Wang JW, Wei CS, Chen LM, Hui WL, Yuan SL, Li JZ, Yang Z, SL Bu: Factors of avascular necrosis of femoral head and osteoporosis in SARS patients’ convalescence. Zhonghua Yi Xue Za Zhi 2004, 84(16):1348-53.
11. Chinese Ministry of Health: Proposal for therapy and diagnosis of SARS,2004 edition issued by Chinese Ministry of Health in 2004. [http://www.idtx.net.cn/editor/UploadFile/200607031059492942.doc]. Accessed 3rd April 2008.
12. Gewaltig M, Mangassner-Stephan K, Gartung C, Bisterfeld S, Gressner AM: Association of polymorphisms of the transforming growth factor-beta1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002, 314(1-2):83-94.
13. Kim YJ, Lee HS, Yoon JH, Kim CY, Park MH, Kim LH, Park BL, Shin HD: Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Human Molecular Genetics 2003, 12(19):2541-2546.
14. Lee SS, Yang YJ, Jiang WH, Lee YJ, Bae HS, Paik KH: Association between TNF-α promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol 2001, 54(9):703-706.
15. Poon LL, Pawlotsky JM, Teknowongse P, Carriere I, Pasquali C, Melero F, et al.: Co-expression of TNF-alpha and IL-1 receptor antagonist in patients infected with hepatitis B virus. Gastroenterology 2004, 127(3):936-944.
16. Pan LH, Ohtani H, Yamauchi K, Nagura H: Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol Int 1996, 46(2):91-9.
17. Pantelidis P, Fanning GC, Wells AU, Welsh KI, Do Bois RM: Analysis of tumor necrosis factor-a, lymphotokin-alpha, tumor necrosis factor receptor II and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 2000, 162(2 Pt 1):755-759.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/8/27/prepub

BMC Infectious Diseases 2008, 8:27